Cargando…
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
The COVID-19 pandemic has elevated mRNA vaccines to global recognition due to their unprecedented success rate in protecting against a deadly virus. This international success is underscored by the remarkable versatility, favorable immunogenicity, and overall safety of the mRNA platform in diverse p...
Autores principales: | Huff, Amanda L., Jaffee, Elizabeth M., Zaidi, Neeha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920340/ https://www.ncbi.nlm.nih.gov/pubmed/35289317 http://dx.doi.org/10.1172/JCI156211 |
Ejemplares similares
-
Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development
por: Zaidi, Neeha, et al.
Publicado: (2020) -
Self-replicating messenger RNA based cancer immunotherapy
por: Lyerly, Herbert Kim
Publicado: (2023) -
Lung cancer immunotherapy: progress, pitfalls, and promises
por: Lahiri, Aritraa, et al.
Publicado: (2023) -
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of
Response to Anti-PD1 Immunotherapy
por: Bigelow, Emma, et al.
Publicado: (2022) -
What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination
por: Redwood, Alec J., et al.
Publicado: (2022)